Molecular characterization of acute myeloid leukemia and its impact on treatment

Olga Frankfurt; Jonathan D. Licht; Martin S. Tallman

doi:10.1097/CCO.0b013e3282f10e55

Molecular characterization of acute myeloid leukemia and its impact on treatment

Olga Frankfurt, Jonathan D. Licht, Martin S. Tallman

Research output: Contribution to journal › Review article › peer-review

25 Scopus citations

Abstract

PURPOSE OF REVIEW: Molecular aberrations are playing an ever increasing role in guiding classification, prognosis, and therapeutic strategies in patients with acute myeloid leukemia. This review outlines recent strides in our understanding of the molecular characteristics of acute myeloid leukemia. RECENT FINDINGS: We highlight the novel concept of preferential co-expression of certain mutations, summarize recent data on the clinically relevant prognostic role of known and novel molecular aberrations, and emphasize the emerging role of gene expression profiling and minimal residual disease monitoring. SUMMARY: We review the molecular heterogeneity within already established categories of acute myeloid leukemia and discuss how these data may translate into prognostic, molecular-based therapy stratification to improve patient outcome.

Original language	English
Pages (from-to)	635-649
Number of pages	15
Journal	Current Opinion in Oncology
Volume	19
Issue number	6
DOIs	https://doi.org/10.1097/CCO.0b013e3282f10e55
State	Published - Nov 2007
Externally published	Yes

Keywords

Acute myeloid leukemia
Acute promyelocytic leukemia
Core-binding factor leukemia
Cytogenetically normal acute myeloid leukemia
Cytogenetics
Molecular analysis

Access to Document

10.1097/CCO.0b013e3282f10e55

Cite this

@article{0876e33b16664ac89f6cf1f13c66392b,

title = "Molecular characterization of acute myeloid leukemia and its impact on treatment",

abstract = "PURPOSE OF REVIEW: Molecular aberrations are playing an ever increasing role in guiding classification, prognosis, and therapeutic strategies in patients with acute myeloid leukemia. This review outlines recent strides in our understanding of the molecular characteristics of acute myeloid leukemia. RECENT FINDINGS: We highlight the novel concept of preferential co-expression of certain mutations, summarize recent data on the clinically relevant prognostic role of known and novel molecular aberrations, and emphasize the emerging role of gene expression profiling and minimal residual disease monitoring. SUMMARY: We review the molecular heterogeneity within already established categories of acute myeloid leukemia and discuss how these data may translate into prognostic, molecular-based therapy stratification to improve patient outcome.",

keywords = "Acute myeloid leukemia, Acute promyelocytic leukemia, Core-binding factor leukemia, Cytogenetically normal acute myeloid leukemia, Cytogenetics, Molecular analysis",

author = "Olga Frankfurt and Licht, {Jonathan D.} and Tallman, {Martin S.}",

year = "2007",

month = nov,

doi = "10.1097/CCO.0b013e3282f10e55",

language = "English",

volume = "19",

pages = "635--649",

journal = "Current Opinion in Oncology",

issn = "1040-8746",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Molecular characterization of acute myeloid leukemia and its impact on treatment

AU - Frankfurt, Olga

AU - Licht, Jonathan D.

AU - Tallman, Martin S.

PY - 2007/11

Y1 - 2007/11

N2 - PURPOSE OF REVIEW: Molecular aberrations are playing an ever increasing role in guiding classification, prognosis, and therapeutic strategies in patients with acute myeloid leukemia. This review outlines recent strides in our understanding of the molecular characteristics of acute myeloid leukemia. RECENT FINDINGS: We highlight the novel concept of preferential co-expression of certain mutations, summarize recent data on the clinically relevant prognostic role of known and novel molecular aberrations, and emphasize the emerging role of gene expression profiling and minimal residual disease monitoring. SUMMARY: We review the molecular heterogeneity within already established categories of acute myeloid leukemia and discuss how these data may translate into prognostic, molecular-based therapy stratification to improve patient outcome.

AB - PURPOSE OF REVIEW: Molecular aberrations are playing an ever increasing role in guiding classification, prognosis, and therapeutic strategies in patients with acute myeloid leukemia. This review outlines recent strides in our understanding of the molecular characteristics of acute myeloid leukemia. RECENT FINDINGS: We highlight the novel concept of preferential co-expression of certain mutations, summarize recent data on the clinically relevant prognostic role of known and novel molecular aberrations, and emphasize the emerging role of gene expression profiling and minimal residual disease monitoring. SUMMARY: We review the molecular heterogeneity within already established categories of acute myeloid leukemia and discuss how these data may translate into prognostic, molecular-based therapy stratification to improve patient outcome.

KW - Acute myeloid leukemia

KW - Acute promyelocytic leukemia

KW - Core-binding factor leukemia

KW - Cytogenetically normal acute myeloid leukemia

KW - Cytogenetics

KW - Molecular analysis

UR - http://www.scopus.com/inward/record.url?scp=34848831463&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e3282f10e55

DO - 10.1097/CCO.0b013e3282f10e55

M3 - Review article

C2 - 17906465

AN - SCOPUS:34848831463

SN - 1040-8746

VL - 19

SP - 635

EP - 649

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

IS - 6

ER -

Molecular characterization of acute myeloid leukemia and its impact on treatment

Abstract

Keywords

Access to Document

Fingerprint

Cite this